| Literature DB >> 18447954 |
Anja Zagrosek1, Ralf Wassmuth, Hassan Abdel-Aty, André Rudolph, Rainer Dietz, Jeanette Schulz-Menger.
Abstract
BACKGROUND: Myocardial edema is a substantial feature of the inflammatory response in human myocarditis. The relation between myocardial edema and myocardial mass in the course of healing myocarditis has not been systematically investigated. We hypothesised that the resolution of myocardial edema as visualised by T2-weighted cardiovascular magnetic resonance (CMR) is associated with a decrease of myocardial mass in steady state free precession (SSFP)-cine imaging.Entities:
Mesh:
Year: 2008 PMID: 18447954 PMCID: PMC2396625 DOI: 10.1186/1532-429X-10-19
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Patients' characteristics
| 1 | Male | 20 | no | ST-Elevation II, III, aVF, V3-5 T-Inversion I, aVL | 443 | Troponin I 39.0 | 125/75 | 110/60 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 2 | Male | 36 | yes | ST-Elevation V5–V9 T-Inversion III, aVF | 407 | Troponin I 8.5 | 138/74 | 146/92 | Metoprolol, Ramipril | None |
| 3 | Male | 50 | yes | ST-Elevation I, II, aVF, V5-6 | 609 | Troponin I 70.0 | 105/70 | n/a | Metoprolol, Ramipril | None |
| 4 | Female | 50 | yes | ST-Elevation V1, V2 T-Inversion I, II, aVL, aVF, V2–V6 | Troponin I 1.3 | 120/70 | 117/49 | Ramipril | Ramipril | |
| 5 | Male | 38 | yes | ST-Elevation II, III, aVF, V5-6 | 213 | Troponin I 15.7 | 130/75 | 110/80 | Ramipril | None |
| 6 | Female | 66 | yes | T-Inversion I, II, aVL, V2-6 | 547 | Troponin T 1.8 | 118/73 | 122/70 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 7 | Male | 51 | yes | ST-Elevation V2-5 T-Inversion III | 349 | Troponin T 1.6 | n/a | 160/96 | Metoprolol, Ramipril | Metoprolol |
| 8 | Female | 24 | yes | AV-Block III | 125 | Troponin T 0.2 | 120/60 | 112/51 | Metoprolol, Candesartan | None |
| 9 | Male | 35 | yes | ST-Elevation I, II, aVF, V1-3, V5-6 | 166 | Troponin T 0.22 | 120/75 | n/a | Ramipril | Ramipril |
| 10 | Male | 26 | no | ST-Elevation I, II, aVF, V4–V6 | 85 | Troponin I 2.0 | 125/80 | 120/80 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 11 | Male | 37 | yes | ST-Elevation I, II, aVL, V4-6 | 1100 | Troponin I 103.0 | 120/75 | 115/70 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 12 | Female | 63 | yes | ST-Elevation I, II, aVL, V5-6 T-Inversion III | 429 | Troponin I 70.1 | 130/75 | 100/60 | Metoprolol, Ramipril | Ramipril |
| 13 | Male | 18 | yes | ST-Elevation II, III, aVF, V5-6 T-Inversion II, III, aVF, V5-6 | 168 | Troponin I 41.0 | 120/70 | 122/56 | Metoprolol, Ramipril | None |
| 14 | Male | 25 | yes | ST-Elevation II, III, aVF | 1767 | Troponin I 198.0 | 115/70 | 130/80 | Metoprolol, Ramipril | Metoprolol |
| 15 | Male | 40 | yes | ST-Elevation I, II, aVL, V5-6 T-Inversion III | 594 | Troponin T 1.0 | n/a | n/a | Metoprolol, Ramipril | None |
| 16 | Male | 18 | no | initially Afib., later ST-Elevation II, aVF, V3-6 | 148 | Troponin I 0.4 | 120/70 | 120/70 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 17 | Male | 67 | yes | ST-Elevation II, III, aVF, V4-6 | 213 | Troponin I 0.4 | 125/75 | 130/80 | Metoprolol, Ramipril | None |
| 18 | Female | 43 | yes | T-Inversion V1–V3 | 205 | Troponin I 0.4 | 120/75 | 130/80 | Metoprolol, Ramipril | Metoprolol, Ramipril |
| 19 | Male | 18 | yes | ST-Elevation I, II | 52 | Troponin I 0.4 | 120/70 | 125/95 | Metoprolol, Ramipril, Torasemid | Metoprolol, Ramipril |
| 20 | Male | 16 | no | ST-Elevation II, III, aVF | 82 | Troponin I 0.3 | 120/70 | 130/80 | Ramipril | Ramipril |
| 21 | Male | 23 | no | ST-Elevation I, II, aVF, V2-5 T-Inversion III | 570 | Troponin I 0.3 | 120/60 | 124/72 | None | None |
Patients' clinical data at admission (Ck: creatine kinase, CAD: coronary artery disease, BP: blood pressure, FU: follow-up)
Figure 1CMR images in the acute (left) and convalescent (right) phase of myocarditis. Upper left: SSFP-cine images showing increased LV mass compared to follow-up (upper right). Lower left: T2-weighted STIR images with higher signal intensity of myocardium compared to follow-up (lower right). [SSFP: steady-state free precession].
Figure 2LV mass in cine-CMR in the acute and convalescent phase (follow-up) of myocarditis (dotted line: mean values of LV mass).
Results of repeated cine-CMR
| 140.90 ± 31.50 | 139.64 ± 31.00 | 1.30 | 0.50 | |
| 0.77 ± 0.15 | 0.78 ± 0.13 | 0.01 | 0.34 | |
| 176.49 ± 29.13 | 174.36 ± 31.11 | 2.09 | 0.43 | |
| 0.97 ± 0.16 | 0.96 ± 0.15 | 0.01 | 0.34 | |
| 61.36 ± 3.70 | 61.73 ± 3.41 | 0.36 | 0.60 | |
| 1.70 ± 0.20 | 1.64 ± 0.21 | 0.06 | 0.65 |
Quantitative results of repeated cine-CMR in volunteers (mean ± SD): LV mass, LV mass/height, LVEDV, LVEDV/height, ejection fraction, T2 ratio
CMR results in acute myocarditis and at follw-up
| 156.66 ± 30.56 | 140.33 ± 28.30 | -16.33 | <0.0001 | |
| 0.90 ± 0.15 | 0.80 ± 0.12 | -0.10 | 0.0001 | |
| 158.10 ± 40.01 | 153.57 ± 37.50 | -4.52 | 0.395 | |
| 0.89 ± 0.19 | 0.85 ± 0.19 | -0.04 | 0.2859 | |
| 59.95 ± 6.39 | 64.14 ± 5.26 | 4.19 | 0.015 | |
| 2.41 ± 0.39 | 1.68 ± 0.29 | -0.72 | <0.0001 |
Quantitative results of CMR in the acute and convalescent phase (follow-up) of myocarditis (mean ± SD): LV mass, LV mass/height, LVEDV, LVEDV/height, ejection fraction, T2 ratio